New Nicotine Products & Cardiovascular Health: What Does the Evidence Say? | #GFN26 Science Lab
September 29, 2026 by gfn.tv
New Nicotine Products & Cardiovascular Health: What Does the Evidence Say? | #GFN26 Science Lab
Cardiovascular risk is one of the places where nicotine policy needs the most precision. New nicotine products should be assessed by what they do to exposure, biomarkers and real-world switching, not by assuming every product carries the same risk as smoking. Cigarettes remain uniquely harmful because combustion drives a major share of cardiovascular damage. The evidence debate should help smokers understand relative risk clearly, while still recognising uncertainty where the science is still developing.
